SU5416 inhibited VEGF and HIF-1α expression through the PI3K/AKT/p70S6K1 signaling pathway

Biochemical and Biophysical Research Communications

Volumn 324, Issue 2, 2004, Pages 471-480

  Zhong, Xiao Song ^a   Zheng, Jenny Z ^a   Reed, Eddie ^a   Jiang, Bing Hua ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

AKT; Angiogenesis; HIF 1 ; Ovarian cancer; P13K; p70S6K1; SU5416; VEGF

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANTINEOPLASTIC AGENT; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; RAPAMYCIN; S6 KINASE; SEMAXANIB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ARTICLE; BINDING SITE; CANCER CELL; CONTROLLED STUDY; DNA BINDING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BINDING SITES; BLOTTING, NORTHERN; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOBLOTTING; INDOLES; LUCIFERASES; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PHOSPHORYLATION; PLASMIDS; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PYRROLES; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; RNA; RNA, MESSENGER; SIGNAL TRANSDUCTION; TETRAZOLIUM SALTS; THIAZOLES; TIME FACTORS; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; TRANSFECTION; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 5144220019     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.09.082     Document Type: Article

References (49)

1. E.S. Bamberger, and C.W. Perrett Angiogenesis in epithelian ovarian cancer Mol. Pathol. 55 2002 348 359
2. R.P. Perez, A.K. Godwin, T.C. Hamilton, and R.F. Ozols Ovarian cancer biology Semin. Oncol. 18 1991 186 204
3. R.T. Greenlee, M.B. Hill-Harmon, T. Murray, and M. Thun Cancer statistics CA Cancer J. Clin. 51 2001 15 36
4. N. Ferrara, and S. Bunting Vascular endothelial growth factor, a specific regulator of angiogenesis Curr. Opin. Nephrol. Hypertens. 5 1996 35 44
5. J. Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease Nat. Med. 1 1995 27 31
6. G. Neufeld, T. Cohen, S. Gengrinovitch, and Z. Poltorak Vascular endothelial growth factor (VEGF) and its receptors FASEB J. 13 1999 9 22
7. A. Abdollahi, K.E. Lipson, X. Han, R. Krempien, T. Trinh, K.J. Weber, P. Hahnfeldt, L. Hlatky, J. Debus, A.R. Howlett, and P.E. Huber SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro Cancer Res. 63 2003 3755 3763
8. F.J. Giles, A.T. Stopeck, L.R. Silverman, J.E. Lancet, M.A. Cooper, A.L. Hannah, J.M. Cherrington, A.M. O'Farrell, H.A. Yuen, S.G. Louie, W. Hong, J.E. Cortes, S. Verstovsek, M. Albitar, S.M. O'Brien, H.M. Kantarjian, and J.E. Karp SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes Blood 102 2003 795 801
9. M. Zangari, E. Anaissie, A. Stopeck, A. Morimoto, N. Tan, J. Lancet, M. Cooper, A. Hannah, G. Garcia-Manero, S. Faderl, H. Kantarjian, J. Cherrington, M. Albitar, and F.J. Giles Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma Clin. Cancer Res. 10 2004 88 95
10. L.S. Rosen Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers Cancer Control 9 2002 36 44
11. W.J. Huss, R.J. Barrios, and N.M. Greenberg SU5416 selectively impairs angiogenesis to induce prostate cancer-specific apoptosis Mol. Cancer Ther. 2 2003 611 616
12. S. Mesiano, N. Ferrara, and R.B. Jaffe Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization Am. J. Pathol. 153 1998 1249 1256
13. Z. Cao, J. Fang, C. Xia, X. Shi, and B.H. Jiang trans-3,4,5′- Trihydroxystibene inhibits hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in human ovarian cancer cells Clin. Cancer Res. 10 2004 5253 5263
14. J. Fang, Z. Cao, Y.C. Chen, E. Reed, and B.H. Jiang 9-beta-d- arabinofuranosyl-2-fluoroadenine inhibits expression of vascular endothelial growth factor through hypoxia-inducible factor-1 in human ovarian cancer cells Mol. Pharmacol. 66 2004 178 186
15. B.H. Jiang, J.Z. Zheng, M. Aoki, and P.K. Vogt Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells Proc. Natl. Acad. Sci. USA 97 2000 1749 1753
16. C.L. Carpenter, B.C. Duckworth, K.R. Auger, B. Cohen, B.S. Schaffhausen, and L.C. Cantley Purification and characterization of phosphoinositide 3-kinase from rat liver J. Biol. Chem. 265 1990 19704 19711
17. H.C. Chen, and J.L. Guan Association of focal adhesion kinase with its potential substrate phosphatidylinositol 3-kinase Proc. Natl. Acad. Sci. USA 91 1994 10148 10152
18. L.C. Cantley The phosphoinositide 3-kinase pathway Science 296 2002 1655 1657
19. B.H. Jiang, M. Aoki, J.Z. Zheng, J. Li, and P.K. Vogt Myogenic signaling of phosphatidylinositol 3-kinase requires the serine-threonine kinase Akt/protein kinase B Proc. Natl. Acad. Sci. USA 96 1999 2077 2081
20. L. Shayesteh, Y. Lu, W.L. Kuo, R. Baldocchi, T. Godfrey, C. Collins, D. Pinkel, B. Powell, G.B. Mills, and J.W. Gray PIK3CA is implicated as an oncogene in ovarian cancer Nat. Genet. 21 1999 99 102
21. M. Aoki, C. Schetter, M. Himly, O. Batista, H.W. Chang, and P.K. Vogt The catalytic subunit of phosphoinositide 3-kinase: requirements for oncogenicity J. Biol. Chem. 275 2000 6267 6275
22. N. Gao, D.C. Flynn, Z. Zhang, X.S. Zhong, V. Walker, K.J. Liu, X. Shi, and B.H. Jiang The G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells Am. J. Physiol. Cell Physiol. 2004
23. B.H. Jiang, F. Agani, A. Passaniti, and G.L. Semenza V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression Cancer Res. 57 1997 5328 5335
24. J. Rak, J. Filmus, G. Finkenzeller, S. Grugel, D. Marme, and R.S. Kerbel Oncogenes as inducers of tumor angiogenesis Cancer Metastasis Rev. 14 1995 263 277
25. G.L. Semenza Hypoxia, clonal selection, and the role of HIF-1 in tumor progression Crit. Rev. Biochem. Mol. Biol. 35 2000 71 103
26. B.H. Jiang, E. Rue, G.L. Wang, R. Roe, and G.L. Semenza Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1 J. Biol. Chem. 271 1996 17771 17778
27. G.L. Wang, B.H. Jiang, E.A. Rue, and G.L. Semenza Hypoxia-inducible factor 1 is a basic-helixâ€"loopâ€"helix-PAS heterodimer regulated by cellular O2 tension Proc. Natl. Acad. Sci. USA 92 1995 5510 5514
28. B.H. Jiang, G. Jiang, J.Z. Zheng, Z. Lu, T. Hunter, and P.K. Vogt Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1 Cell Growth Differ. 12 2001 363 369
29. N.V. Iyer, L.E. Kotch, F. Agani, S.W. Leung, E. Laughner, R.H. Wenger, M. Gassmann, J.D. Gearhart, A.M. Lawler, A.Y. Yu, and G.L. Semenza Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha Genes Dev. 12 1998 149 162
30. E. Maltepe, J.V. Schmidt, D. Baunoch, C.A. Bradfield, and M.C. Simon Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT Nature 386 1997 403 407
31. H.E. Ryan, J. Lo, and R.S. Johnson HIF-1 alpha is required for solid tumor formation and embryonic vascularization EMBO J. 17 1998 3005 3015
32. X. Zhong, Q.Q. Li, and E. Reed SU5416 sensitizes ovarian cancer cells to cisplatin through inhibition of nucleotide excision repair Cell. Mol. Life Sci. 60 2003 794 802
33. N. Gao, Z. Zhang, B.H. Jiang, and X. Shi Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer Biochem. Biophys. Res. Commun. 310 2003 1124 1132
34. B.H. Jiang, J.Z. Zheng, and P.K. Vogt An essential role of phosphatidylinositol 3-kinase in myogenic differentiation Proc. Natl. Acad. Sci. USA 95 1998 14179 14183
35. P.H. Maxwell, G.U. Dachs, J.M. Gleadle, L.G. Nicholls, A.L. Harris, I.J. Stratford, O. Hankinson, C.W. Pugh, and P.J. Ratcliffe Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth Proc. Natl. Acad. Sci. USA 94 1997 8104 8109
36. M.S. Neshat, I.K. Mellinghoff, C. Tran, B. Stiles, G. Thomas, R. Petersen, P. Frost, J.J. Gibbons, H. Wu, and C.L. Sawyers Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR Proc. Natl. Acad. Sci. USA 98 2001 10314 10319
37. Z.Q. Yuan, M. Sun, R.I. Feldman, G. Wang, X. Ma, C. Jiang, D. Coppola, S.V. Nicosia, and J.Q. Cheng Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer Oncogene 19 2000 2324 2330
38. H.W. Chang, M. Aoki, D. Fruman, K.R. Auger, A. Bellacosa, P.N. Tsichlis, L.C. Cantley, T.M. Roberts, and P.K. Vogt Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase Science 276 1997 1848 1850
39. A. Besson, S.M. Robbins, and V.W. Yong PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis Eur. J. Biochem. 263 1999 605 611
40. A. Di Cristofano, and P.P. Pandolfi The multiple roles of PTEN in tumor suppression Cell 100 2000 387 390
41. M. Esteller, J. Xercavins, and J. Reventos Advances in the molecular genetics of endometrial cancer (Review) Oncol. Rep. 6 1999 1377 1382
42. J. Li, C. Yen, D. Liaw, K. Podsypanina, S. Bose, S.I. Wang, J. Puc, C. Miliaresis, L. Rodgers, R. McCombie, S.H. Bigner, B.C. Giovanella, M. Ittmann, B. Tycko, H. Hibshoosh, M.H. Wigler, and R. Parsons PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer Science 275 1997 1943 1947
43. B.K. Rasheed, R.N. Wiltshire, S.H. Bigner, and D.D. Bigner Molecular pathogenesis of malignant gliomas Curr. Opin. Oncol. 11 1999 162 167
44. P.A. Steck, M.A. Pershouse, S.A. Jasser, W.K. Yung, H. Lin, A.H. Ligon, L.A. Langford, M.L. Baumgard, T. Hattier, T. Davis, C. Frye, R. Hu, B. Swedlund, D.H. Teng, and S.V. Tavtigian Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers Nat. Genet. 15 1997 356 362
45. Y. Qian, L. Corum, Q. Meng, J. Blenis, J.Z. Zheng, X. Shi, D.C. Flynn, and B.H. Jiang PI3K induced actin filament remodeling through Akt and p70S6K1: implication of essential role in cell migration Am. J. Physiol. Cell Physiol. 286 2004 C153 C163
46. K. Podsypanina, R.T. Lee, C. Politis, I. Hennessy, A. Crane, J. Puc, M. Neshat, H. Wang, L. Yang, J. Gibbons, P. Frost, V. Dreisbach, J. Blenis, Z. Gaciong, P. Fisher, C. Sawyers, L. Hedrick-Ellenson, and R. Parsons An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice Proc. Natl. Acad. Sci. USA 98 2001 10320 10325
47. J.M. Peralba, L. DeGraffenried, W. Friedrichs, L. Fulcher, V. Grunwald, G. Weiss, and M. Hidalgo Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in cancer patients Clin. Cancer Res. 9 2003 2887 2892
48. M. Hidalgo, and E.K. Rowinsky The rapamycin-sensitive signal transduction pathway as a target for cancer therapy Oncogene 19 2000 6680 6686
49. H.D. Skinner, X.S. Zhong, N. Gao, X. Shi, and B.H. Jiang Arsenite induces p70S6K1 activation and HIF-1alpha expression in prostate cancer cells Mol. Cell. Biochem. 255 2004 19 23